The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
onle those approvals likely to push stock to 100p or higher especially the the US approval of Alkindi in September is very important thats what drives the stock up ahead of these approvals . Another big milestones is a US Partner for Chronocort which also could hit the wire anytime now .. Market cap of 49 million is very very cheap for a Biotech that could be profitable within 12-18 months .STRONG BUY
definitely a terrible underpriced stock with MASSIVE upside potential .
Market Cap £41 million
Cash £15 million
Price 33p
Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
Woodford never owned this one
DNL = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL
Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
Stock is still a PURE GIFT at current valuation of only 28 million .Company moving closer to approval of Alkindi and Chronocort with commercial opportunity north of $300 million . Another major sp driver will be the US Partnership which could hit the wire any day now this means HUGE upfront payment to DNL .2020 couldbe the year of DNL .GL
Price 33p-- Market Cap £28.7 million
US FDA Accepts for Review Diurnal’s New Drug Application for Alkindi® Sprinkle
Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents
NDA could potentially be approved in Q3 2020
Chronocort® Marketing Authorisation Application Submitted in Europe
Significant opportunity to address unmet patient need, in a market estimated at $250 million
Marketing authorisation anticipated in Q1 2021
Strong interest in Alkindi® and Chronocort® from potential US partners and we expect to conclude a US licensing deal in H1 2020
GREAT News out today ..NDA accepted by FDA and the Drug could be approved in Q3 .. Still the CHEAPEST and most attractive small cap Biotech in UK . A potential 10 Bagger here
Diurnal : US FDA Accepts NDA Application for Alkindi
https://www.marketscreener.com/DIURNAL-GROUP-PLC-25531374/news/Diurnal-US-FDA-Accepts-NDA-Application-for-Alkindi-29990468/
Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents
NDA could potentially be approved in Q3 2020
Diurnal (DNL)
Market Cap £23 M
Price: 28p
New Presentation
https://www.diurnal.co.uk/media/https://www.diurnal.co.uk/media/36790/interim-results-presentation-february-2020-pp.pdf/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf
DCF valuation of 202p per share
https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf
Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
Upcoming Catalysts:
MAA-Acceptance for Chronocort in February/March 2020
Alkindi approval in Israel expected in 2Q 2020
Alkindi approval in Australien expected in 2Q 2020
US-Partnership for Alkindi & Chronocort expected in 1H 2020
Alkindi & Chronocort Partnership for Asia für Japan und China
US-Approval for Alkindi expected in 4Q 2020
EU Approval for Chronocort expected in 4Q/1Q 2020/21
$88m market opportunity (Europe and US) for Paediatric AI (inc CAH)
$351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia
$2,767m market opportunity (Europe and US) for Adrenal Insufficiency
GREAT NEWS OUT
Market cap £25 million
Chronocort MAA Submitted in Europe
[url]https://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/chronocort-maa-submitted-in-europe/201912160700079030W/[/url]
Significant opportunity to address unmet patient need, in a market estimated at $250 million
Marketing authorisation anticipated in Q1 2021
DNL still the cheapest and most attractive biotech in GB .I screnned all GB Biotech and there is no better smallcap than this .
****************************/articles/diurnal-group-surges-on-successful-testosterone-clinical-study-95dd288/
He added: “We look forward to engaging with regulators in the US and Europe to progress DITEST™ to late stage clinical trials, and to discussing these positive trial data with potential development and commercialisation partners ."
Diurnal believes the product could be the first effective oral native testosterone treatment in what it estimates to be a $4.8 billion global market.
Great news out today and much more to come ...
Diurnal (DNL) Price:30p --Market Cap £26 M --Cash £9 M--MEGA milestones expected within 4 weeks = 300-500% GEM
Approaching anumber of near-term milestones....5 November 2019
https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf
Valuation -DCF 202p per share
The consequence of the Chronocort trial outcome is minimal in the bigger picture, as it has delayed both the EMA MAA submission and the start of the US Phase III trial only by about six months. Hence, there has not been a material change to our DCF valuation based on our clearly-stated assumptions in ourresearch note, published on 25 April 2019. The net present value of the cashflows that could be generated from DNL’s first two products equates to £305m. Risk-adjustment to take account of the different stages of development in different territories reduces this to £171m, or 202p per share.
DITEST™(Hypogonadism) study readout Q4 2019
Alkindi® US NDA submission to the FDA(paediatric AI,including CAH)Q4 2019
Chronocort® European regulatory submission to the EMA(CAH)Q4 2019
Conclude US partnering discussions for Alkindi®(Chronocort®)H1 2020
Presentation
https://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf
nobody interested in this pure undiscovered goldmine ? you guys should learn to buy low and sell high and not the other way around hehe .Get some and be happy with all the big news on the way
OVB is good but risky because it has a long way to go untill approval i the large markets of Europe and USA ,,the much hotter play with massive milestones around the corner is the undiscovered stock DNL which is well financed and has terrible low valuation of only £32 million. she is running higher again today up 6%+ ,, Hardman has a fair value of 225p per share DNL still trading at laughable 41p
Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Risk-adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
MAA submission for Chronocort approval in Q4 2019
Alkindi approval in Israel expected in 1H 2020
Alkindi approval in Australia expected in 1H 2020
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
“Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.
DNL is well financed , terrible underpriced at around 32 Million and has great pipeline with multiple milestones around the corner which could push this low float stock quickly close or even above 100p .STRONG BUY
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
MAA submission for Chronocort approval in Q4 2019
Alkindi approval in Israel expected in 1H 2020
Alkindi approval in Australia expected in 1H 2020
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
“Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.
OVB is good but risky the much hotter play with massive milestones around the corner is the undiscovered stock DNL which is well financed and has terrible low valuation of only £32 million..thank me later guys
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
MAA submission for Chronocort approval in Q4 2019
Alkindi approval in Israel expected in 1H 2020
Alkindi approval in Australia expected in 1H 2020
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
“Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.
OVB & DNL cheapest UK listed companies ,,, undiscovered Diurnal (DNL) is close to approval for 2 drugs in USA and Europe expected next year targeting $500+ market (market cap only 32 million ) ..
small consolidation ongoing after the nice jump , any dip here is a gift here with lots of big news on the way . DNL is still the most attractive and underpriced UK-Biotech .GL
going up step by step and company is still heavily undervalued at market cap of 39 million and the best is still to come during 2H 2019 .STRONG BUY
Shareholders here should put high gtc sell order in like 100p ,so your shares willnot available for shorts and more important it reduces the free shares on market so it helps the stock to make even much bigger jumpf on good news . Thank you guys
How to Prevent your Shares Holdings from being Shorted
Q:What can you do to prevent your shares holdings from being shorted?
A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.
There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps :D.
Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.
In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
the last 4 months will be MASSIVE for this dirt cheap stock valued at laughable 36 million there is NO cheaper nor bigger opportunity in the UK pharma sector than our undiscovered DNL . Stock coming from over 200p in the end for no reason so DNL shouldtrade noth 150p+ for just what they reached to date if not higher .
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
EMA submission for Chronocort approval in Q4 2019
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.
upfront payments alone from potential US-Partner(s) for Alkindi and Chronocort could be higher than the whole DNL valuation of 35 million . Dont be surprised if this brutally undervalued company getting acquired .
wait till news hit the wire then you will be happy to get some under 100p and a lot of news is on the way ...
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
EMA submission for Chronocort approval in Q4 2019
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.